Mumps: MMR vaccination and genetic diversity of mumps virus, 2007-2011 in Catalonia, Spain.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
09 Nov 2019
Historique:
received: 10 03 2019
accepted: 23 09 2019
entrez: 11 11 2019
pubmed: 11 11 2019
medline: 15 1 2020
Statut: epublish

Résumé

Mumps is a vaccine-preventable disease but outbreaks have been reported in persons vaccinated with two doses of MMR vaccine. The objective was to describe the demographic features, vaccination effectiveness and genetic mumps virus diversity among laboratory-confirmed cases between 2007 and 2011 in Catalonia. Cases and outbreaks of mumps notified to the notifiable diseases system of Catalonia between 2007 and 2011 retrospectively registered were included. Public health care centres provided written immunization records to regional public health staff to determine the vaccination history. Saliva and serum specimens were collected from suspected cases for laboratory-confirmation using real-time reverse-transcriptase PCR (rtRT-PCR) or serological testing. Phylogenetic analysis of the complete SH gene (316 nucleotides) and complete coding HN protein (1749 nucleotides) sequences was made. Categorical variables were compared using the Chi-square or Fisher's tests and continuous variables using the Student test. Vaccination effectiveness by number of MMR doses was estimated using the screening method. During the study period, 581 confirmed cases of mumps were notified (incidence rate 1.6 cases/100,000 persons-year), of which 60% were male. Three hundred sixty-four laboratory-confirmed cases were reported, of which 44% were confirmed by rtRT-PCR. Of the 289 laboratory-confirmed cases belonging to vaccination cohorts, 33.5% (97) had received one dose of MMR vaccine and 50% (145) two doses. Based on phylogenetic analyses of 316-nucleotide and 174-nucleotide SH sequences, the viruses belonging to viral genotypes were: genotype G (126), genotype D (23), genotype H (2), genotype F (2), genotype J (1), while one remained uncharacterized. Amino acid differences were detected between circulating strains and the Jeryl Lynn vaccine strains, although the majority of amino acid substitutions were genotype-specific. Fifty-one outbreaks were notified that included 324 confirmed mumps cases. Genotype G was the most frequent genotype detected. The family (35%), secondary schools (25%) and community outbreaks (18%) were the most frequent settings. Our study shows that genotype G viruses are the most prevalent in Catalonia. Most cases occurred in people who had received two doses of MMR, suggesting inadequate effectiveness of the Jeryl Lynn vaccine strain. The possible factors related are discussed.

Sections du résumé

BACKGROUND BACKGROUND
Mumps is a vaccine-preventable disease but outbreaks have been reported in persons vaccinated with two doses of MMR vaccine. The objective was to describe the demographic features, vaccination effectiveness and genetic mumps virus diversity among laboratory-confirmed cases between 2007 and 2011 in Catalonia.
METHODS METHODS
Cases and outbreaks of mumps notified to the notifiable diseases system of Catalonia between 2007 and 2011 retrospectively registered were included. Public health care centres provided written immunization records to regional public health staff to determine the vaccination history. Saliva and serum specimens were collected from suspected cases for laboratory-confirmation using real-time reverse-transcriptase PCR (rtRT-PCR) or serological testing. Phylogenetic analysis of the complete SH gene (316 nucleotides) and complete coding HN protein (1749 nucleotides) sequences was made. Categorical variables were compared using the Chi-square or Fisher's tests and continuous variables using the Student test. Vaccination effectiveness by number of MMR doses was estimated using the screening method.
RESULTS RESULTS
During the study period, 581 confirmed cases of mumps were notified (incidence rate 1.6 cases/100,000 persons-year), of which 60% were male. Three hundred sixty-four laboratory-confirmed cases were reported, of which 44% were confirmed by rtRT-PCR. Of the 289 laboratory-confirmed cases belonging to vaccination cohorts, 33.5% (97) had received one dose of MMR vaccine and 50% (145) two doses. Based on phylogenetic analyses of 316-nucleotide and 174-nucleotide SH sequences, the viruses belonging to viral genotypes were: genotype G (126), genotype D (23), genotype H (2), genotype F (2), genotype J (1), while one remained uncharacterized. Amino acid differences were detected between circulating strains and the Jeryl Lynn vaccine strains, although the majority of amino acid substitutions were genotype-specific. Fifty-one outbreaks were notified that included 324 confirmed mumps cases. Genotype G was the most frequent genotype detected. The family (35%), secondary schools (25%) and community outbreaks (18%) were the most frequent settings.
CONCLUSIONS CONCLUSIONS
Our study shows that genotype G viruses are the most prevalent in Catalonia. Most cases occurred in people who had received two doses of MMR, suggesting inadequate effectiveness of the Jeryl Lynn vaccine strain. The possible factors related are discussed.

Identifiants

pubmed: 31706275
doi: 10.1186/s12879-019-4496-z
pii: 10.1186/s12879-019-4496-z
pmc: PMC6842476
doi:

Substances chimiques

Measles-Mumps-Rubella Vaccine 0
Viral Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

954

Subventions

Organisme : Instituto de Salud Carlos III
ID : 2017/SGR 1342

Investigateurs

Josep Álvarez (J)
César Arias (C)
Irene Barrabeig (I)
Neus Camps (N)
Mónica Carol (M)
Pere Godoy (P)
Ana Martínez (A)
Sofia Minguell (S)
Ignasi Parrón (I)
Ma Rosa Sala (MR)
Ariadna Rovira (A)
Núria Torner (N)
Cristina Rius (C)

Références

Clin Infect Dis. 2008 Dec 1;47(11):1458-67
pubmed: 18959494
J Clin Virol. 2006 Nov;37(3):184-9
pubmed: 16971175
Vaccine. 2008 Jul 4;26(29-30):3601-7
pubmed: 18539365
J Infect Dis. 2009 Feb 15;199(4):552-60
pubmed: 19113988
Rev Med Virol. 2015 Mar;25(2):85-101
pubmed: 25424978
JAMA. 2000 Nov 22-29;284(20):2643-7
pubmed: 11086376
Hum Vaccin Immunother. 2015;11(1):282-7
pubmed: 25483547
Pediatrics. 2012 Dec;130(6):e1567-74
pubmed: 23129075
Epidemiol Infect. 2017 Nov;145(15):3219-3225
pubmed: 28903791
Vaccine. 2001 Feb 8;19(13-14):1727-31
pubmed: 11166897
N Engl J Med. 2012 Nov;367(18):1704-13
pubmed: 23113481
Vaccine. 2012 Apr 19;30(19):2999-3002
pubmed: 22381073
N Engl J Med. 2017 Sep 7;377(10):947-956
pubmed: 28877026
Pediatrics. 2007 Oct;120(4):e862-8
pubmed: 17908742
BMC Infect Dis. 2017 Jan 10;17(1):56
pubmed: 28068914
J Med Virol. 2009 Oct;81(10):1819-25
pubmed: 19697404
J Infect. 2005 Nov;51(4):294-8
pubmed: 16291282
MMWR Recomm Rep. 2013 Jun 14;62(RR-04):1-34
pubmed: 23760231
Emerg Infect Dis. 2007 Jan;13(1):12-7
pubmed: 17370510
Emerg Infect Dis. 2014 Apr;20(4):643-8
pubmed: 24655811
BMJ. 1999 Aug 7;319(7206):352
pubmed: 10435956
J Clin Microbiol. 2010 Sep;48(9):3288-94
pubmed: 20660212
Infect Genet Evol. 2016 Nov;45:145-150
pubmed: 27590714
J Clin Microbiol. 2005 Apr;43(4):1869-78
pubmed: 15815011
J Pediatr. 1968 Apr;72(4):461-6
pubmed: 4869563
Mol Biol Evol. 2011 Oct;28(10):2731-9
pubmed: 21546353
Bull World Health Organ. 1985;63(6):1055-68
pubmed: 3879673
Vaccine. 2009 Oct 19;27(44):6186-95
pubmed: 19815120
Pediatr Infect Dis J. 2013 Apr;32(4):374-80
pubmed: 23099425
Wkly Epidemiol Rec. 2012 Jun 1;87(22):217-24
pubmed: 24340404
PLoS One. 2013 Apr 24;8(4):e61791
pubmed: 23637906
N Engl J Med. 1967 Feb 2;276(5):245-51
pubmed: 6016060
N Engl J Med. 2008 Apr 10;358(15):1580-9
pubmed: 18403766
J Clin Microbiol. 2010 Apr;48(4):1245-54
pubmed: 20107099
Epidemiol Infect. 2013 Jun;141(6):1298-309
pubmed: 22954346
Vaccine. 2004 Jul 29;22(21-22):2713-6
pubmed: 15246601
Vaccine. 2006 Mar 24;24(14):2662-8
pubmed: 16309801
Vaccine. 2005 Jul 1;23(31):4070-4
pubmed: 15950329
Commun Dis Public Health. 2002 Dec;5(4):311-3
pubmed: 12564247
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W14-8
pubmed: 20439312
MMWR Morb Mortal Wkly Rep. 2018 Jan 12;67(1):33-38
pubmed: 29324728

Auteurs

Irene Barrabeig (I)

Epidemiological Surveillance and Response to Public Health Emergencies Unit in Barcelona South, Agency of Public Health of Catalonia, Generalitat of Catalonia., Hospital Universitari de Bellvitge, Edifici antiga escola d'infermeria, 3a planta, Feixa Llarga, s/n, 08907, L'Hospitalet de Llobregat, Spain. ibarrabeig@gencat.cat.
CIBER Epidemiología y Salud Pública, Institut of Health Carlos III, Madrid, Spain. ibarrabeig@gencat.cat.

Andrés Antón (A)

Virology Unit, Centre de Diagnòstic Biomèdic, Hospital Clínic, Barcelona, Spain.

Núria Torner (N)

Epidemiological Surveillance and Response to Public Health Emergencies Unit in Barcelona South, Agency of Public Health of Catalonia, Generalitat of Catalonia., Hospital Universitari de Bellvitge, Edifici antiga escola d'infermeria, 3a planta, Feixa Llarga, s/n, 08907, L'Hospitalet de Llobregat, Spain.
CIBER Epidemiología y Salud Pública, Institut of Health Carlos III, Madrid, Spain.
Department of Medicine, University of Barcelona, Barcelona, Spain.

Tomàs Pumarola (T)

Virology Unit, Centre de Diagnòstic Biomèdic, Hospital Clínic, Barcelona, Spain.

Josep Costa (J)

Virology Unit, Centre de Diagnòstic Biomèdic, Hospital Clínic, Barcelona, Spain.
CIBER Enfermedades Hepáticas y Digestivas, Institute of Health Carlos III, Madrid, Spain.

Àngela Domínguez (À)

CIBER Epidemiología y Salud Pública, Institut of Health Carlos III, Madrid, Spain.
Department of Medicine, University of Barcelona, Barcelona, Spain.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH